Global Insulin Delivery Devices Market (By Type - Insulin Pen, Insulin Vial & Syringes and Insulin Pumps; By Region - Europe, North America & Asia Pacific) Market Outlook 2024

November 2018 | 124 pages | ID: GAA33D5E272EN
Rockville Research

Abstracts

Insulin delivery devices have evolved in a big way from conventional metal syringes to intelligent insulin pens and implantable Continuous Glucose Monitoring (CGM) system for glycemic control in people with diabetes. In the year 2018, FDA approved Senseonics' Eversense continuous glucose monitoring (CGM) system, the first implantable CGM in the United States.

The report “Global Insulin Delivery Device Market – (By Type-Vials & Syringes, Insulin Pens & Insulin Pumps; By Region- North America, Europe & Asia Pacific) Market Outlook 2024” provides an in-depth analysis of global insulin as well as insulin delivery devices market across segments such as Vials & Syringes, Insulin Pens & Insulin Pumps. Market outlook for insulin delivery devices market overall as well as across various sub-segments has been provided for the period 2018-24. Regional analysis is done across major markets in North America, Europe and Asia Pacific.

The report provides comprehensive coverage on major industry drivers, restraints, and their impact on market growth during the forecast period. Furthermore, the study encompasses various market specific growth opportunities in global insulin delivery devices market. The report has been segmented as following:-

Market Segments

• Vials & Syringes
• Insulin Pens
• Insulin Pumps

Geographical Coverage

• North America - The US
• Europe
• Asia Pacific

Key Vendors

• Novo Nordisk
• Sanofi Aventis
• Eli Lilly and Company
• Merck & Co.

Contents

1. EXECUTIVE SUMMARY

2. RESEARCH METHODOLOGY

3. INSULIN MARKET

3.1 Background
  3.1.1 Cost – Human & Financial
3.2 Overview
3.3 Insulin Delivery Devices
  3.3.1 Vials & Syringes
  3.3.2 Insulin Pens
  3.3.3 Insulin Pumps

4. MARKET ANALYSIS

4.1 Insulin Market
  4.1.1 Market Sizing (Actual & Forecasted)
  4.1.2 Market Share by Insulin Type
  4.1.3 Market Share by Segment
  4.1.4 Market Share by Region
4.2 Insulin Delivery Devices
  4.2.1 Market Sizing (Actual & Forecasted)
  4.2.2 Market Share by Devices
  4.2.3 Market Share by End-User
  4.2.4 Market Share by Region

5. INSULIN DELIVERY DEVICES – MARKET SEGMENTATION

5.1 Vials and Syringes
  5.1.1 Overview
  5.1.2 Market Sizing (Actual & Forecasted)
5.2 Insulin Pens
  5.2.1 Overview
  5.2.2 Market Sizing (Actual & Forecasted)
  5.2.3 Market Share by End-User
5.3 Insulin Pumps
  5.3.1 Overview
  5.3.2 Market Sizing (Actual & Forecasted)
5.4 Others

6. REGIONAL ANALYSIS

6.1 Europe
  6.1.1 Overview
  6.1.2 Market Sizing (Actual & Forecasted)
  6.1.3 Germany
      6.1.3.1.1 Market Sizing (Actual & Forecasted)
6.2 North America and Caribbean
  6.2.1 Overview
  6.2.2 Market Sizing (Actual & Forecasted)
  6.2.3 The US
      6.2.3.1.1 Market Sizing (Actual & Forecasted)
      6.2.3.1.2 Market Share by Product
6.3 Asia Pacific
  6.3.1 Overview
  6.3.2 Market Sizing (Actual & Forecasted)
  6.3.3 China
      6.3.3.1.1 Market Sizing (Actual & Forecasted)

7. PRICING ANALYSIS

8. GLOBAL INSULIN MARKET DYNAMICS

8.1 Industry Trends & Developments
  8.1.1 Closed-Looped Insulin Delivery/Artificial Pancreas System
  8.1.2 Implantable Continuous Glucose Monitoring (CGM) System
  8.1.3 Advent of Intelligent Insulin Pens
  8.1.4 Next-Generation Insulin Management System Platform
8.2 Growth Drivers
  8.2.1 Increasing Incidences of Diabetes
  8.2.2 Rise in Geriatric Population
  8.2.3 Growing Obese Population
  8.2.4 Propagation of Diabetes Management Awareness
  8.2.5 Government Impetus
8.3 Challenges
  8.3.1 High Cost of Insulin Pumps
  8.3.2 Insurance Coverage issue
  8.3.3 Regulatory Pressure
  8.3.4 Technological Issue

9. COMPETITIVE LANDSCAPE

9.1 Insulin Market
9.2 Insulin Delivery Devices
  9.2.1 Insulin Delivery Devices Market
  9.2.2 Insulin Pens Market
  9.2.3 Insulin Pumps Market

10. COMPANY PROFILES

10.1 Novo Nordisk
10.2 Sanofi Aventis
10.3 Eli Lilly and Company
10.4 Merck & Co.